A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
PHASE3
This study is a Phase III, international, multicenter, randomized, controll...
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
PHASE2
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib...
Status
Recruiting
Location
Beijing Chest Hospital,Capital Medical Unniversity